ANAPTYSBIO, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations
ANAPTYSBIO, INC. (ANAB) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations of $0 as of 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations · last filed 2026-09-21
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations $0.00.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations $100.00M.
- 2025-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations $100.00M.
- 2024-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations $100.00M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations |
|---|---|
| 2026-06-30 | $0.00 10-KT · filed 2026-09-21 |
| 2025-12-31 | $100.00M 10-KT · filed 2026-09-21 |
| 2025-06-30 | $100.00M 10-KT · filed 2026-09-21 |
| 2024-12-31 | $100.00M 10-KT · filed 2026-09-21 |
| 2023-12-31 | $100.00M 10-KT · filed 2026-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |